Sagimet Biosciences Inc. (SGMT) Stock

Sagimet Biosciences Inc. (SGMT) is a Healthcare stock trading at $6.67 (as of 2026-06-18), with a market capitalization of $237.36M and a trailing P/E of -5.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sagimet Biosciences Inc. is a biopharmaceutical company developing therapies that target fatty acid synthase (FASN) for conditions involving lipid metabolism dysfunction. Its pipeline includes Denifanstat for nonalcoholic steatohepatitis and acne and TVB-3567 for certain cancers.

Valuation — source: SEC EDGAR (first-party)
Price$6.67
Market Cap$237.36M
P/E Ratio-5.4
Price / Book2.32
Price / Sales118.68
DCF Value (model)$-22.94
DCF Upside vs Price-443.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.00M
Net Margin-1393.8%
Return on Equity-42.5%
Current Ratio20.34
Valuation vs Sector & Industry
Stock P/E-5.4
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-125.9%
vs Industry-131.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($7.46M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEODavid A. Happel
Employees14
CountryUS
IPO Date2023-07-17

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Organigram Global Inc. (OGI)
  • Nuvectis Pharma, Inc. (NVCT)
  • Kalaris Therapeutics Inc (KLRS)
  • Cardiff Oncology, Inc. (CRDF)
  • Climb Bio, Inc. (CLYM)
  • Journey Medical Corporation (DERM)
  • Cartesian Therapeutics, Inc. (RNAC)
  • Quince Therapeutics, Inc. (QNCX)
SGMT earnings history · SGMT institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.